Published in Br J Pharmacol on July 01, 2005
Adenosine kinase: exploitation for therapeutic gain. Pharmacol Rev (2013) 1.26
Cardiac purinergic signalling in health and disease. Purinergic Signal (2014) 0.81
Remote ischemic preconditioning in patients with intermittent claudication. Clinics (Sao Paulo) (2013) 0.77
Repeated Remote Ischemic Conditioning Effect on Ankle-brachial Index in Diabetic Patients - A Randomized Control Trial. Adv Biomed Res (2017) 0.75
Protection against infarction afforded by preconditioning is mediated by A1 adenosine receptors in rabbit heart. Circulation (1991) 4.30
Preconditioning the myocardium: from cellular physiology to clinical cardiology. Physiol Rev (2003) 3.83
Regional ischemic 'preconditioning' protects remote virgin myocardium from subsequent sustained coronary occlusion. Circulation (1993) 3.68
Myocardial protection by brief ischemia in noncardiac tissue. Circulation (1996) 2.91
Adenosine produces nitric oxide and prevents mitochondrial oxidant damage in rat cardiomyocytes. Cardiovasc Res (2005) 1.87
Reduction of reperfusion injury in the canine preparation by intracoronary adenosine: importance of the endothelium and the no-reflow phenomenon. Circulation (1987) 1.35
Sites of action of adenosine in interorgan preconditioning of the heart. Am J Physiol Heart Circ Physiol (2002) 1.17
Cardioprotection 'outside the box'--the evolving paradigm of remote preconditioning. Basic Res Cardiol (2003) 1.15
Myocardial protective effects of adenosine. Infarct size reduction with pretreatment and continued receptor stimulation during ischemia. Circulation (1992) 1.06
Receptor-mediated cardioprotective effects of endogenous adenosine are exerted primarily during reperfusion after coronary occlusion in the rabbit. Circulation (1993) 0.97
Effects of ischemic and adenosine preconditioning on interstitial fluid adenosine and myocardial infarct size. Am J Physiol (1995) 0.95
Ischemic preconditioning: exploring the paradox. Prog Cardiovasc Dis (1998) 0.92
Limitation of infarct size in rabbit hearts by the novel adenosine receptor agonist AMP 579 administered at reperfusion. J Mol Cell Cardiol (2000) 0.89
Intravenous adenosine protects the myocardium primarily by activation of a neurogenic pathway. Br J Pharmacol (2005) 0.87
Comparison of interstitial fluid and coronary venous adenosine levels in in vivo porcine myocardium. J Mol Cell Cardiol (1998) 0.84
Intramyocardial injections and protection against myocardial ischemia. An attempt to examine the cardioprotective actions of adenosine. Circulation (1996) 0.81
Survival and development of neonatal rat cardiomyocytes transplanted into adult myocardium. J Mol Cell Cardiol (2002) 3.79
Human semilunar cardiac valve remodeling by activated cells from fetus to adult: implications for postnatal adaptation, pathology, and tissue engineering. Circulation (2006) 2.68
Matrix metalloproteinase-13/collagenase-3 deletion promotes collagen accumulation and organization in mouse atherosclerotic plaques. Circulation (2005) 2.01
Measurement of collagen and smooth muscle cell content in atherosclerotic plaques using polarization-sensitive optical coherence tomography. J Am Coll Cardiol (2007) 1.82
Aging mouse hearts are refractory to infarct size reduction with post-conditioning. J Am Coll Cardiol (2008) 1.43
Postconditioning via stuttering reperfusion limits myocardial infarct size in rabbit hearts: role of ERK1/2. Am J Physiol Heart Circ Physiol (2005) 1.37
Rebuilding a damaged heart: long-term survival of transplanted neonatal rat cardiomyocytes after myocardial infarction and effect on cardiac function. Circulation (2002) 1.32
Remote ischemic preconditioning: current knowledge, unresolved questions, and future priorities. J Cardiovasc Pharmacol Ther (2011) 1.24
Cardioprotection with postconditioning: loss of efficacy in murine models of type-2 and type-1 diabetes. Antioxid Redox Signal (2010) 1.17
Authorship and characteristics of articles in pharmacy journals: changes over a 20-year interval. Ann Pharmacother (2011) 1.17
Cardioprotection 'outside the box'--the evolving paradigm of remote preconditioning. Basic Res Cardiol (2003) 1.15
Macrophage colony-stimulating factor treatment after myocardial infarction attenuates left ventricular dysfunction by accelerating infarct repair. J Am Coll Cardiol (2006) 1.08
Pharmacy-managed anticoagulation: assessment of in-hospital efficacy and evaluation of financial impact and community acceptance. J Thromb Thrombolysis (2006) 1.07
Autophagy as a therapeutic target for ischaemia /reperfusion injury? Concepts, controversies, and challenges. Cardiovasc Res (2012) 1.04
Genetically engineered resistance for MMP collagenases promotes abdominal aortic aneurysm formation in mice infused with angiotensin II. Lab Invest (2009) 1.01
Effect of chronic kidney disease on warfarin management in a pharmacist-managed anticoagulation clinic. J Manag Care Pharm (2011) 1.00
Adaptation of a photochemical method to initiate recurrent platelet-mediated thrombosis in small animals. Lasers Med Sci (2007) 0.93
The gap junction uncoupler heptanol abrogates infarct size reduction with preconditioning in mouse hearts. Cardiovasc Pathol (2002) 0.92
Lamina propria cellularity and collagen composition: an integrated assessment of structure in humans. Ann Otol Rhinol Laryngol (2009) 0.89
Mechanisms of myocardial ischemic preconditioning are age related: PKC-epsilon does not play a requisite role in old rabbits. J Appl Physiol (1985) (2003) 0.86
Venous thromboembolism in an industrial north american city: temporal distribution and association with particulate matter air pollution. PLoS One (2013) 0.84
Collagen fiber morphology determines echogenicity of myocardial scar: implications for image interpretation. Echocardiography (2006) 0.83
Genesis of remote conditioning: action at a distance--'hypotheses non fingo'? J Cardiovasc Med (Hagerstown) (2013) 0.83
The effect of cognitive impairment in the elderly on the initial and long-term stability of warfarin therapy. Drugs Aging (2012) 0.81
First molecular evidence that inositol trisphosphate signaling contributes to infarct size reduction with preconditioning. Am J Physiol Heart Circ Physiol (2006) 0.81
Pretreatment with D-myo-inositol trisphosphate reduces infarct size in rabbit hearts: role of inositol trisphosphate receptors and gap junctions in triggering protection. J Pharmacol Exp Ther (2005) 0.81
In vitro platelet responsiveness to adenosine-mediated "preconditioning" is age-dependent. J Thromb Thrombolysis (2005) 0.81
Cardioprotection via adaptation to hypoxia: expanding the timeline and targets? Basic Res Cardiol (2011) 0.79
Reduction of infarct size with D-myo-inositol trisphosphate: role of PI3-kinase and mitochondrial K(ATP) channels. Am J Physiol Heart Circ Physiol (2005) 0.79
Hypoechoic areas on ultrasound images of atheroma are not always diagnostic of fatty plaque. Ultrasound Med Biol (2005) 0.78
Kidney dysfunction at the time of intracerebral hemorrhage is associated with increased in-hospital mortality: a retrospective observational cohort study. Neurol Res (2012) 0.77
Remote ischemic conditioning and renal function after contrast-enhanced CT scan: A randomized trial. Clin Invest Med (2015) 0.76
Warfarin maintenance dose in older patients: higher average dose and wider dose frequency distribution in patients of African ancestry than those of European ancestry. Blood Cells Mol Dis (2010) 0.76
Point-of-care assessment of platelet reactivity in the emergency department may facilitate rapid rule-out of acute coronary syndromes: a prospective cohort pilot feasibility study. BMJ Open (2014) 0.75
Brief apnea induces myocardial ischemic tolerance by an opioid-insensitive mechanism. Cardiovasc Pathol (2004) 0.75
Ventricular remodeling after myocardial infarction and effects of ACE inhibition on hemodynamics and scar formation in SHR. Cardiovasc Pathol (2002) 0.75